Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2022-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_da2cd7fdf7d3484cb8d2a58d02ed8d1b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Amrita Goyal, MD |e author |
| 700 | 1 | 0 | |a Damodaran Narayanan, MBBS, PhD |e author |
| 700 | 1 | 0 | |a Waihay Wong, MD, PhD |e author |
| 700 | 1 | 0 | |a Alvaro C. Laga, MD |e author |
| 700 | 1 | 0 | |a Nathan T. Connell, MD, MPH |e author |
| 700 | 1 | 0 | |a Susan Y. Ritter, MD, PhD |e author |
| 700 | 1 | 0 | |a Gabriela Cobos, MD |e author |
| 245 | 0 | 0 | |a Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome |
| 260 | |b Elsevier, |c 2022-05-01T00:00:00Z. | ||
| 500 | |a 2352-5126 | ||
| 500 | |a 10.1016/j.jdcr.2022.02.022 | ||
| 546 | |a EN | ||
| 690 | |a autoinflammatory | ||
| 690 | |a myelodysplasia | ||
| 690 | |a relapsing polychondritis | ||
| 690 | |a tocilizumab | ||
| 690 | |a UB1A | ||
| 690 | |a ubiquitination | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n JAAD Case Reports, Vol 23, Iss , Pp 15-19 (2022) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2352512622001072 | |
| 787 | 0 | |n https://doaj.org/toc/2352-5126 | |
| 856 | 4 | 1 | |u https://doaj.org/article/da2cd7fdf7d3484cb8d2a58d02ed8d1b |z Connect to this object online. |